<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995383</url>
  </required_header>
  <id_info>
    <org_study_id>WP28586</org_study_id>
    <nct_id>NCT01995383</nct_id>
  </id_info>
  <brief_title>A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.</brief_title>
  <official_title>A Single Oral Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Subjects Including a Single Intravenous Microdose of RO6836191</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This single-center, randomized, placebo-controlled, double-blind study will assess the
      safety, pharmacokinetics and pharmacodynamics of RO6836191 in healthy male volunteers in two
      parts. Part 1 will assess the safety of oral single ascending doses of RO6836191 compared to
      placebo in fasted volunteers. In Part 2, participants will be given two single oral doses of
      RO6836191 or placebo under low or normal-salt diet conditions. A subset of these participants
      will subsequently receive a single IV dose of RO6836191 for further analysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 2: Area under the concentration-time curve (AUC)</measure>
    <time_frame>Up to Day 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Plasma aldosterone levels</measure>
    <time_frame>Up to 2 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Urine aldosterone levels</measure>
    <time_frame>Up to 3 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Plasma aldosterone levels</measure>
    <time_frame>Up to Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Urine aldosterone levels</measure>
    <time_frame>Up to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Incidence of AEs</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1: Incidence of adverse events (AE)</measure>
    <time_frame>Until Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Volume of distribution after intravenous administration</measure>
    <time_frame>Days 28-37</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Part 1: Placebo (PL)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Single Ascending Doses (SAD) of RO6836191</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: PL: NS followed by LS diet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: RO6836191: LS followed by NS diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: RO6836191: NS followed by LS diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LS followed by NS diet condition</intervention_name>
    <description>LS diet period followed by NS diet period</description>
    <arm_group_label>Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet</arm_group_label>
    <arm_group_label>Part 2: RO6836191: LS followed by NS diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NS followed by LS diet condition</intervention_name>
    <description>NS diet period followed by LS diet period</description>
    <arm_group_label>Part 2: PL: NS followed by LS diet</arm_group_label>
    <arm_group_label>Part 2: RO6836191: NS followed by LS diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single oral administrations</description>
    <arm_group_label>Part 1: Placebo (PL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 single oral administrations</description>
    <arm_group_label>Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet</arm_group_label>
    <arm_group_label>Part 2: PL: NS followed by LS diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6836191</intervention_name>
    <description>Orally administered, single ascending doses</description>
    <arm_group_label>Part 1: Single Ascending Doses (SAD) of RO6836191</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6836191</intervention_name>
    <description>2 single oral doses</description>
    <arm_group_label>Part 2: RO6836191: LS followed by NS diet</arm_group_label>
    <arm_group_label>Part 2: RO6836191: NS followed by LS diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6836191</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet</arm_group_label>
    <arm_group_label>Part 2: PL: NS followed by LS diet</arm_group_label>
    <arm_group_label>Part 2: RO6836191: LS followed by NS diet</arm_group_label>
    <arm_group_label>Part 2: RO6836191: NS followed by LS diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers, aged 18 to 45 years old.

          -  No active or chronic disease following a detailed medical and surgical history and
             complete physical examination.

          -  A BMI between 18 to 30 kg/m2 inclusive.

          -  Use of a highly effective form of birth control for the duration of the study and
             until 90 days after the last dose.

        Exclusion Criteria:

          -  Any clinically relevant current or history of conditions or illnesses.

          -  Clinically significant symptoms of infection within 5 days of the first dosing day or
             a history of recurrent infections.

          -  Any suspicion or history of alcohol abuse and/or consumption of other drugs of abuse.

          -  Smokers unable or unwilling to restrict to 5 cigarettes daily during the study and to
             not smoke during the stay at the clinic.

          -  Any cardiac abnormalities.

          -  Blood donation over 450 mL within three months prior to screening.

          -  Participation in an investigational drug or device study within 3 months prior to
             dosing.

          -  Corticosteroid use within 3 months prior to dosing.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2013</study_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

